Germany-based molecular diagnostics company SIRS-Lab has enrolled first patient in a 1000-patient clinical study evaluating molecular pathogen test VYOO.

The multicenter trial, performed in 11 key centers across Germany and initiated in February 2011, will deliver data about the utility of the PCR test compared to conventional methods to identify microbes in ICU patients with suspected sepsis.

The study, led by the president of the German Sepsis Society Tobias Welte (Hannover), will deliver data about the sensitivity and specificity of VYOO compared with the current standard blood culture and the clinical diagnosis at the hospital.

It will evaluate how VYOO supports the clinician’s decision-making and delivers critical information to support early and targeted anti-infective therapy.